ElonMusk was not it out for biotech. And that is a ridiculous comparison, like saying what if Steve Jobs was a doctor?
It’s silly, if he were it might be that he was a success or it might not be. What he chose and when he chose it and what it involved were all a part of the decision making and also very much about timing for certain technologies.
The reality is, this management team got this drug to this stage, despite the odd that caused 400+ other trials and very many companies to fail completely by this stage.
So your comparison disregards reality for a made-up fantasy of what ifs. That’s nonsense.
And again, nothing has been launched yet, so the notion you ditch the management team that created the success for some random dude who likely is conflicted and sold-out the existing shareholders before he takes the job. That is what this kind of conversation is almost always about. People pushing for radical measures out of the blue. It’s called a hostile takeover, and usually it means a cheaper than hoped for buyout with a hostile bid suggesting the company “isn’t doing well” that is intended in fact to suppress the price and undermine the impression of success.
News 
Market Data 
Discover 
